Product menu

A woman with shingles rash on her forehead

THIS IS SHINGLES

Shingles pain can be severe, disabling, and last for weeks1

SHINGRIX is not indicated for the treatment of HZ or its complications, such as pain.

SHINGRIX is indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older and in adults 18 years of age or older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.1

Nearly everyone ≥50 years old is at risk for shingles and should be protected against it

≥90% of Canadians have had varicella and are at risk for shingles.2
Age-related decline in immunity is the dominant driver of shingles.3
Approximately 1/3 of people will develop shingles during their lifetime, with 2/3 of cases occurring in those aged ≥50 years.1

Meet patients who are at risk of shingles

Image of Jennifer

Meet Jennifer, 52*

Learn more
Image of Sanjay

Meet Sanjay, 66*

Learn more
Image of John

Meet John, 70*

Learn more
Image of KARL

Meet Karl, 56*

Learn more

* Fictitious case. May not be representative of all patients.

Virus icon

Did you know age is the dominant driver of shingles?

Learn about age-related decline in immunity.3

Learn more
Graph icon

Efficacy data for SHINGRIX1

Vaccine efficacy profile was studied in subjects aged ≥50 years (ZOE-50) and subjects aged ≥70 years (ZOE-70), at risk of shingles due to age-related decline in immunity. SHINGRIX efficacy profile was also studied in two immunocompromised patient populations aged ≥18 years.

Learn more
Checkmark icon

SHINGRIX: Recommendations from NACI

Review the recommendations on the use of SHINGRIX by the National Advisory Committee on Immunization (NACI).4

Learn more
RESOURCES FOR YOUR PRACTICE

INCORPORATING SHINGRIX INTO YOUR PRACTICE

Incorporating SHINGRIX into your practice involves proper administration, discussing disease risk and vaccination, and ensuring series completion.

VISIT THE VIDEO CENTRE

Visit the video centre to view videos related to the design of SHINGRIX, reconstitution instructions, recommendations, and much more!

Important Safety Information

Indications and clinical use:

  • SHINGRIX is indicated for the prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older and in adults 18 years of age or older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy

Contraindications:

  • Individuals with a known hypersensitivity to the active substance or to any component of the vaccine

Most serious warnings and precautions:

  • Administration: Do not administer the vaccine intravascularly, intradermally or subcutaneously

Other relevant warnings and precautions:

  • A protective immune response may not be elicited in all vaccinees
  • Not for prevention of primary varicella infection or treatment of HZ or postherpetic neuralgia
  • Postpone in those with acute severe febrile illness
  • Use with caution in those with thrombocytopenia or any coagulation disorder
  • Syncope following or before any vaccination as a psychogenic response
  • Fever and shivering were more frequent when the 23-valent pneumococcal polysaccharide (PPV23) vaccine was co-administered with SHINGRIX
  • Use in special populations such as pregnant or nursing women or pediatrics (<18 years of age) has not been established
  • Increased risk of Guillain-Barré syndrome was observed in a post-marketing observational study in individuals 65 years of age or older within 42 days following vaccination (estimated 3 excess cases per million doses administered), with insufficient information available to determine a causal relationship with SHINGRIX

For more information:

Please consult the Product Monograph at gsk.ca/SHINGRIX/PM for important information relating to dosing and administration, adverse reactions and drug interactions which have not been discussed in this piece. To request a Product Monograph, or to report an adverse event, please call 1-800-387-7374.

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. National Advisory Committee on Immunization (NACI). Statement on the recommended use of herpes zoster vaccine. Can Commun Dis Rep 2010;36(ACS-1):1–19.
  3. Harpaz R, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR-5):1–30.
  4. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24